Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease – guidance (TA684)

NICE recommend nivolumab as an option for the adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease.

National Institute for Health and Care Excellence